Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results
By Voyager Therapeutics, Inc.
Published - Nov 08, 2022, 07:04 AM ET
Last Updated - Jul 25, 2024, 08:03 AM EDT
- Voyager’s TRACERTMcapsid platform validated by Pfizer option exercise -
- Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER -
- Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 -
- Conference call at 8:30 a.m. ET today -